Global Vascular Endothelial Growth Factor (VEGF) Inhibitor Market Report 2024

Vascular Endothelial Growth Factor (VEGF) Inhibitor Global Market Report 2024 – By Drugs Type (Avastin, Tecentriq, Lucentis, Tagrisso, Cometriq, Eylea, Other Drug Types), By Route Of Administration (Oral, Intravenous, Intravitreal), By Application (Oncology, Ophthalmology, Other Applications) – Market Size, Trends, And Global Forecast 2024-2033

Starting Price : $5000.00 | Pages : 250 | Published : January 2024 | Delivery Time: 2-3 business days | Format : pdf

Need assistance or more information before the purchase?

Enquire Before Buying
Vascular Endothelial Growth Factor (VEGF) Inhibitor Market

Proud Members Of

checkslacipN checkaoirsN checkscipN

Vascular Endothelial Growth Factor (VEGF) Inhibitor Market Definition And Segments

A VEGF inhibitor is an inhibitor that prevents planned cell death by acting as an anti-apoptotic factor for hematopoietic cells. VEGF increases vascular permeability, which may make it easier for tumors to spread via the bloodstream and receive more oxygen and nutrients.

The main types of vascular endothelial growth factor (VEGF) inhibitors are Avastin, Tecentriq, Cometriq, Eylea, and others. Avastin is a medication that helps people with wet age-related macular degeneration (AMD). It can also be employed to treat diabetic eye problems and other retinal issues. It's administered into the eye to help delay the loss of eyesight caused by certain disorders. The different routes of administration include oral, and intravenous and are used in oncology, ophthalmology, and others.

The vascular endothelial growth factor (VEGF) inhibitor market covered in this report is segmented –

1) By Drugs Type: Avastin, Tecentriq, Lucentis, Tagrisso, Cometriq, Eylea, Other Drug Types

2) By Route Of Administration: Oral, Intravenous, Intravitreal

3) By Application: Oncology, Ophthalmology, Other Applications

The vascular endothelial growth factor (VEGF) inhibitor market size has grown strongly in recent years. It will grow from $9.68 billion in 2023 to $10.46 billion in 2024 at a compound annual growth rate (CAGR) of 8.0%. The growth in the historic period can be attributed to increase in cancer prevalence, strong economic growth in emerging markets, increase in pharmaceutical R&D expenditure, increased healthcare expenditure, government initiatives and rapid growth in elderly population.

The vascular endothelial growth factor (VEGF) inhibitor market size is expected to see strong growth in the next few years. It will grow to $13.98 billion in 2028 at a compound annual growth rate (CAGR) of 7.5%. The growth in the forecast period can be attributed to increasing prevalence of cancer, rising prevalence of age-related macular degeneration (AMD), rise in healthcare expenditure, high potential of emerging economies, high penetration of the biosimilar drugs and increasing geriatric population. Major trends in the forecast period include offering combination therapies to patients in order to combat advanced cancers and improve patient life, focusing on strategic collaborations to boost innovations and establish category leadership, investing extensively in R&D activities for the development of effective and innovative drugs, focusing on the production of biosimilars in order to cater to a wider market by making treatment more affordable and focusing on reducing dosages for wet age-related macular degeneration (AMD) in order to improve patient welfare.

The Increasing Prevalence Of Cancer And Macular Degeneration Diseases Drives The VEGF Inhibitor Market Growth.

The growing prevalence of cancer and macular degeneration diseases is expected to drive the VEGF inhibitor market. For instance, in August 2022, according to this systematic review and meta-analysis published by the National Library of Medicine, a US-based medical library, age-related macular degeneration will affect 8–7% of the global population, with the illness affecting 196 million individuals in 2020 and rising to 288 million by 2040. Anti-vascular endothelial growth factor (anti-VEGF) agents halt the progression of the disease and improve vision. A vascular endothelial growth factor (VEGF) inhibitor slows and restricts tumor growth during cancers. Hence, the rising prevalence of cancer along with macular degeneration disease aids in the vascular endothelial growth factor (VEGF) inhibitor market growth over the forecast period.

The Increasing Prevalence Of Diabetic Retinopathy Drives The VEGF Inhibitor Market Growth

The increasing prevalence of diabetic retinopathy is expected to drive the growth of the vascular endothelial growth factor (VEGF) inhibitor market going forward. Diabetic retinopathy is a diabetes-related eye condition that affects the retina, which is the light-sensitive tissue located at the back of the eye. VEGF inhibitors, also known as anti-VEGF medications, play a significant role in treating diabetic retinopathy as they are used to inhibit VEGF, a protein that plays a key role in the growth of blood vessels, and its overproduction is associated with the development of abnormal blood vessels in the eye, which can lead to diabetic retinopathy. For instance, in 2021, according to Prevent Blindness, a US-based volunteer eye health and safety organization, diabetic retinopathy (DR) affected an estimated 9.6 million people in the United States (26.4% of those with diabetes), and vision-threatening diabetic retinopathy (VTDR) affected 1.84 million people (5.1% of those with diabetes). Therefore, the increasing prevalence of diabetic retinopathy is driving the growth of the vascular endothelial growth factor (VEGF) inhibitor market.

Major companies operating in the vascular endothelial growth factor (VEGF) inhibitor market report are F. Hoffmann-La Roche AG, Bayer AG, Regeneron Pharmaceuticals Inc., Astrazeneca Plc., Novartis AG, Pfizer Inc., Eli Lilly and Company, Exelixis Inc., Amgen Inc., Sanofi S.A., Cipla Limited, Biocon, Dr. Reddy's Laboratories, Chi-Med, Innovent Biologics, Daiichi Sankyo, Chugai Pharmaceutical Co. Ltd., AstraZeneca PLC, Allergan plc., Boehringer Ingelheim International GmbH, GlaxoSmithKline PLC, Ipsen, Oxurion, AVEO Oncology, Pharmstandard Group, Zentiva, Coherus BioSciences Inc., Celgene, Exelixis Inc., Regeneron Pharmaceuticals Inc., AVEO pharmaceuticals, Eisai Co. Ltd.

Side Effects Hinder VEGF Inhibitor Market Growth

Side effects caused by VEGF inhibitors are expected to hinder the vascular endothelial growth factor (VEGF) inhibitor market. Side effects of treatment with VEGF-targeting angiogenesis inhibitors include hemorrhage and clots in the arteries, which results in a stroke or heart attack, hypertension, reversible posterior leukoencephalopathy syndrome, and impaired wound healing, and protein in the urine. For instance, Bevacizumab, a biosimilar drug approved by FDA, has side effects such as impaired wound healing, hypertension, bleeding, and gastrointestinal perforations. Side effects caused by VEGF inhibitors hinder the VEGF inhibitor market growth.

Collaborations Drive Product Portfolio Expansion

Key players operating in the VEGF inhibitor industry are undergoing various collaborations and partnerships to expand their product portfolio by developing new products. Product portfolio expansion is the strategic approach that companies use to grow their businesses and increase their market share by satisfying consumer demand. The process of product development includes conceptualization, design, development, and marketing of newly created or newly rebranded goods or services. For instance, in September 2021, AbbVie, a US-based pharmaceutical company, partnered with REGENXBIO Inc., a US-based biotechnology company, to develop and commercialize RGX-314, an experimental gene therapy for chronic retinal illnesses such as diabetic retinopathy, wet age-related macular degeneration, and others. RGX-314 consists of the NAV AAV8 vector, which encodes an antibody fragment designed to inhibit vascular endothelial growth factor (VEGF). It is believed that RGX-314 blocks the VEGF pathway, which is responsible for the development of new, leaky blood vessels and the subsequent fluid buildup in the retina. In accordance with the terms of the contract, AbbVie will make a $370 million upfront payment to REGENXBIO, with the possibility of subsequent payments totaling up to $1.38 billion upon achievement of additional development, regulatory, and commercial milestones.

Collaboration Drives Innovation In VEGF Inhibitors

Major companies operating in the VEGF inhibitors market are focused on introducing innovative products with the help of collaboration with one another to maximize their revenues in the market. Collaborative innovation refers to a strategic approach to developing new ideas, products, or services through collaboration with external partners, such as customers, suppliers, and other stakeholders. For instance, in June 2022, Biogen Inc., a US-based biotechnology company, and Samsung Bioepis Co. Ltd., a South Korea-based biopharmaceutical company, launched the BYOOVIZ (ranibizumab-nuna), a biosimilar referencing LUCENTIS (ranibizumab). The introduction of BYOOVIZ, the first ophthalmology biosimilar in the United States, is a significant step in expanding the alternatives and lowering the cost of the existing anti-VEGF treatments. Myopic Choroidal Neovascularization (mCNV), Macular Edema Following Retinal Vein Occlusion (RVO), and Neovascular (Wet) Age-Related Macular Degeneration (AMD) are all conditions that can be treated with BYOOVIZ, a vascular endothelial growth factor (VEGF) inhibitor.

Takeda Acquires Global License For VEGFR Inhibitor

In January 2023, Takeda Pharmaceutical Company Limited, a Japan-based pharmaceutical company, acquired the worldwide license of Fruquintinib, a highly selective oral VEGFR1/2/3 tyrosine kinase inhibitor, from HUTCHMED Limited for an undisclosed amount. In accordance with the terms of the agreement, Takeda will be granted a sole global license to create and market fruquintinib for all indications and regions outside of mainland China, Hong Kong, and Macau. HUTCHMED Limited is a China-based pharmaceutical company that develops vascular endothelial growth factor receptor (VEGFR) 1/2/3.

North America was the largest region in the vascular endothelial growth factor (VEGF) inhibitor market in 2023. Middle East is expected to be the fastest-growing region in the vascular endothelial growth factor (VEGF) inhibitor market share during the forecast period. The regions covered in the vascular endothelial growth factor (VEGF) inhibitor market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

The countries covered in the vascular endothelial growth factor (VEGF) inhibitor market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Italy, Canada, Spain

The vascular endothelial growth factor (VEGF) inhibitor market consists of sales of nexavar, sunitinib, nilotinib, pazopanib, and dasatinib. Values in this market are factory gate values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

The vascular endothelial growth factor (VEGF) inhibitor market research report is one of a series of new reports from The Business Research Company that provides vascular endothelial growth factor (VEGF) inhibitor market statistics, including vascular endothelial growth factor (VEGF) inhibitor industry global market size, regional shares, competitors with a vascular endothelial growth factor (VEGF) inhibitor market share, detailed vascular endothelial growth factor (VEGF) inhibitor market segments, market trends and opportunities, and any further data you may need to thrive in the vascular endothelial growth factor (VEGF) inhibitor industry. This vascular endothelial growth factor (VEGF) inhibitor market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

Vascular Endothelial Growth Factor (VEGF) Inhibitor Market Report Scope
Report AttributeDetails
Market Size Value In 2024 $10.46 billion
Revenue Forecast In 2033 $13.98 billion
Growth Rate CAGR of 7.5% from 2024 to 2033
Base Year For Estimation 2023
Actual Estimates/Historical Data 2018-2023
Forecast Period 2024 - 2028 - 2033
Market Representation Revenue in USD Billion and CAGR from 2024 to 2033
Segments Covered 1) By Drugs Type: Avastin, Tecentriq, Lucentis, Tagrisso, Cometriq, Eylea, Other Drug Types
2) By Route Of Administration: Oral, Intravenous, Intravitreal
3) By Application: Oncology, Ophthalmology, Other Applications
Regional Scope Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
Country Scope Australia; China; India; Indonesia; Japan; South Korea; Bangladesh; Thailand; Vietnam; Malaysia; Singapore; Philippines; Hong Kong; New Zealand; USA; Canada; Mexico; Brazil; Chile; Argentina; Colombia; Peru; France; Germany; UK; Austria; Belgium; Denmark; Finland; Ireland; Italy; Netherlands; Norway; Portugal; Spain; Sweden; Switzerland; Russia; Czech Republic; Poland; Romania; Ukraine; Saudi Arabia; Israel; Iran; Turkey; UAE; Egypt; Nigeria; South Africa
Key Companies Profiled F. Hoffmann-La Roche AG; Bayer AG; Regeneron Pharmaceuticals Inc.; Astrazeneca Plc.; Novartis AG; Pfizer Inc.; Eli Lilly and Company; Exelixis Inc.; Amgen Inc.; Sanofi S.A.; Cipla Limited; Biocon; Dr. Reddy's Laboratories; Chi-Med; Innovent Biologics; Daiichi Sankyo; Chugai Pharmaceutical Co. Ltd; AstraZeneca plc; Allergan plc.; Boehringer Ingelheim International GmbH; GlaxoSmithKline plc; Ipsen; Oxurion; AVEO Oncology; Pharmstandard Group; Zentiva; Coherus BioSciences Inc.; Celgene; Exelixis Inc.; Regeneron Pharmaceuticals Inc.; AVEO pharmaceuticals; Eisai Co. Ltd.
Customization ScopeRequest for Sample
Pricing And Purchase OptionsExplore Purchase Options

    Table Of Contents

    1. Executive Summary

    2. Vascular Endothelial Growth Factor (VEGF) Inhibitor Market Characteristics

    3. Vascular Endothelial Growth Factor (VEGF) Inhibitor Market Trends And Strategies

    4. Vascular Endothelial Growth Factor (VEGF) Inhibitor Market - Macro Economic Scenario

    4.1. Impact Of High Inflation On The Market

    4.2. Ukraine-Russia War Impact On The Market

    4.3. COVID-19 Impact On The Market

    5. Global Vascular Endothelial Growth Factor (VEGF) Inhibitor Market Size and Growth

    5.1. Global Vascular Endothelial Growth Factor (VEGF) Inhibitor Market Drivers and Restraints

    5.1.1. Drivers Of The Market

    5.1.2. Restraints Of The Market

    5.2. Global Vascular Endothelial Growth Factor (VEGF) Inhibitor Historic Market Size and Growth, 2018 - 2023, Value ($ Billion)

    5.3. Global Vascular Endothelial Growth Factor (VEGF) Inhibitor Forecast Market Size and Growth, 2023 - 2028, 2033F, Value ($ Billion)

    6. Vascular Endothelial Growth Factor (VEGF) Inhibitor Market Segmentation

    6.1. Global Vascular Endothelial Growth Factor (VEGF) Inhibitor Market, Segmentation By Drugs Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    Avastin

    Tecentriq

    Cometriq

    Eylea

    Other Drug Types

    6.2. Global Vascular Endothelial Growth Factor (VEGF) Inhibitor Market, Segmentation By Route Of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    Oral

    Intravenous

    6.3. Global Vascular Endothelial Growth Factor (VEGF) Inhibitor Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    Oncology

    Ophthalmology

    Other Applications

    7. Vascular Endothelial Growth Factor (VEGF) Inhibitor Market Regional And Country Analysis

    7.1. Global Vascular Endothelial Growth Factor (VEGF) Inhibitor Market, Split By Region, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    7.2. Global Vascular Endothelial Growth Factor (VEGF) Inhibitor Market, Split By Country, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    8. Asia-Pacific Vascular Endothelial Growth Factor (VEGF) Inhibitor Market

    8.1. Asia-Pacific Vascular Endothelial Growth Factor (VEGF) Inhibitor Market Overview

    Region Information, Impact Of COVID-19, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies

    8.2. Asia-Pacific Vascular Endothelial Growth Factor (VEGF) Inhibitor Market, Segmentation By Drugs Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    8.3. Asia-Pacific Vascular Endothelial Growth Factor (VEGF) Inhibitor Market, Segmentation By Route Of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    8.4. Asia-Pacific Vascular Endothelial Growth Factor (VEGF) Inhibitor Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    9. China Vascular Endothelial Growth Factor (VEGF) Inhibitor Market

    9.1. China Vascular Endothelial Growth Factor (VEGF) Inhibitor Market Overview

    9.2. China Vascular Endothelial Growth Factor (VEGF) Inhibitor Market, Segmentation By Drugs Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion

    9.3. China Vascular Endothelial Growth Factor (VEGF) Inhibitor Market, Segmentation By Route Of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion

    9.4. China Vascular Endothelial Growth Factor (VEGF) Inhibitor Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion

    10. India Vascular Endothelial Growth Factor (VEGF) Inhibitor Market

    10.1. India Vascular Endothelial Growth Factor (VEGF) Inhibitor Market, Segmentation By Drugs Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    10.2. India Vascular Endothelial Growth Factor (VEGF) Inhibitor Market, Segmentation By Route Of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    10.3. India Vascular Endothelial Growth Factor (VEGF) Inhibitor Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    11. Japan Vascular Endothelial Growth Factor (VEGF) Inhibitor Market

    11.1. Japan Vascular Endothelial Growth Factor (VEGF) Inhibitor Market Overview

    11.2. Japan Vascular Endothelial Growth Factor (VEGF) Inhibitor Market, Segmentation By Drugs Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    11.3. Japan Vascular Endothelial Growth Factor (VEGF) Inhibitor Market, Segmentation By Route Of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    11.4. Japan Vascular Endothelial Growth Factor (VEGF) Inhibitor Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    12. Australia Vascular Endothelial Growth Factor (VEGF) Inhibitor Market

    12.1. Australia Vascular Endothelial Growth Factor (VEGF) Inhibitor Market, Segmentation By Drugs Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    12.2. Australia Vascular Endothelial Growth Factor (VEGF) Inhibitor Market, Segmentation By Route Of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    12.3. Australia Vascular Endothelial Growth Factor (VEGF) Inhibitor Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    13. Indonesia Vascular Endothelial Growth Factor (VEGF) Inhibitor Market

    13.1. Indonesia Vascular Endothelial Growth Factor (VEGF) Inhibitor Market, Segmentation By Drugs Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    13.2. Indonesia Vascular Endothelial Growth Factor (VEGF) Inhibitor Market, Segmentation By Route Of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    13.3. Indonesia Vascular Endothelial Growth Factor (VEGF) Inhibitor Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    14. South Korea Vascular Endothelial Growth Factor (VEGF) Inhibitor Market

    14.1. South Korea Vascular Endothelial Growth Factor (VEGF) Inhibitor Market Overview

    14.2. South Korea Vascular Endothelial Growth Factor (VEGF) Inhibitor Market, Segmentation By Drugs Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    14.3. South Korea Vascular Endothelial Growth Factor (VEGF) Inhibitor Market, Segmentation By Route Of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    14.4. South Korea Vascular Endothelial Growth Factor (VEGF) Inhibitor Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    15. Western Europe Vascular Endothelial Growth Factor (VEGF) Inhibitor Market

    15.1. Western Europe Vascular Endothelial Growth Factor (VEGF) Inhibitor Market Overview

    15.2. Western Europe Vascular Endothelial Growth Factor (VEGF) Inhibitor Market, Segmentation By Drugs Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    15.3. Western Europe Vascular Endothelial Growth Factor (VEGF) Inhibitor Market, Segmentation By Route Of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    15.4. Western Europe Vascular Endothelial Growth Factor (VEGF) Inhibitor Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    16. UK Vascular Endothelial Growth Factor (VEGF) Inhibitor Market

    16.1. UK Vascular Endothelial Growth Factor (VEGF) Inhibitor Market, Segmentation By Drugs Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    16.2. UK Vascular Endothelial Growth Factor (VEGF) Inhibitor Market, Segmentation By Route Of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    16.3. UK Vascular Endothelial Growth Factor (VEGF) Inhibitor Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    17. Germany Vascular Endothelial Growth Factor (VEGF) Inhibitor Market

    17.1. Germany Vascular Endothelial Growth Factor (VEGF) Inhibitor Market, Segmentation By Drugs Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    17.2. Germany Vascular Endothelial Growth Factor (VEGF) Inhibitor Market, Segmentation By Route Of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    17.3. Germany Vascular Endothelial Growth Factor (VEGF) Inhibitor Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    18. France Vascular Endothelial Growth Factor (VEGF) Inhibitor Market

    18.1. France Vascular Endothelial Growth Factor (VEGF) Inhibitor Market, Segmentation By Drugs Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    18.2. France Vascular Endothelial Growth Factor (VEGF) Inhibitor Market, Segmentation By Route Of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    18.3. France Vascular Endothelial Growth Factor (VEGF) Inhibitor Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    19. Italy Vascular Endothelial Growth Factor (VEGF) Inhibitor Market

    19.1. Italy Vascular Endothelial Growth Factor (VEGF) Inhibitor Market, Segmentation By Drugs Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    19.2. Italy Vascular Endothelial Growth Factor (VEGF) Inhibitor Market, Segmentation By Route Of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    19.3. Italy Vascular Endothelial Growth Factor (VEGF) Inhibitor Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    20. Spain Vascular Endothelial Growth Factor (VEGF) Inhibitor Market

    20.1. Spain Vascular Endothelial Growth Factor (VEGF) Inhibitor Market, Segmentation By Drugs Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    20.2. Spain Vascular Endothelial Growth Factor (VEGF) Inhibitor Market, Segmentation By Route Of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    20.3. Spain Vascular Endothelial Growth Factor (VEGF) Inhibitor Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    21. Eastern Europe Vascular Endothelial Growth Factor (VEGF) Inhibitor Market

    21.1. Eastern Europe Vascular Endothelial Growth Factor (VEGF) Inhibitor Market Overview

    21.2. Eastern Europe Vascular Endothelial Growth Factor (VEGF) Inhibitor Market, Segmentation By Drugs Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    21.3. Eastern Europe Vascular Endothelial Growth Factor (VEGF) Inhibitor Market, Segmentation By Route Of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    21.4. Eastern Europe Vascular Endothelial Growth Factor (VEGF) Inhibitor Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    22. Russia Vascular Endothelial Growth Factor (VEGF) Inhibitor Market

    22.1. Russia Vascular Endothelial Growth Factor (VEGF) Inhibitor Market, Segmentation By Drugs Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    22.2. Russia Vascular Endothelial Growth Factor (VEGF) Inhibitor Market, Segmentation By Route Of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    22.3. Russia Vascular Endothelial Growth Factor (VEGF) Inhibitor Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    23. North America Vascular Endothelial Growth Factor (VEGF) Inhibitor Market

    23.1. North America Vascular Endothelial Growth Factor (VEGF) Inhibitor Market Overview

    23.2. North America Vascular Endothelial Growth Factor (VEGF) Inhibitor Market, Segmentation By Drugs Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    23.3. North America Vascular Endothelial Growth Factor (VEGF) Inhibitor Market, Segmentation By Route Of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    23.4. North America Vascular Endothelial Growth Factor (VEGF) Inhibitor Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    24. USA Vascular Endothelial Growth Factor (VEGF) Inhibitor Market

    24.1. USA Vascular Endothelial Growth Factor (VEGF) Inhibitor Market Overview

    24.2. USA Vascular Endothelial Growth Factor (VEGF) Inhibitor Market, Segmentation By Drugs Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    24.3. USA Vascular Endothelial Growth Factor (VEGF) Inhibitor Market, Segmentation By Route Of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    24.4. USA Vascular Endothelial Growth Factor (VEGF) Inhibitor Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    25. Canada Vascular Endothelial Growth Factor (VEGF) Inhibitor Market

    25.1. Canada Vascular Endothelial Growth Factor (VEGF) Inhibitor Market Overview

    25.2. Canada Vascular Endothelial Growth Factor (VEGF) Inhibitor Market, Segmentation By Drugs Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    25.3. Canada Vascular Endothelial Growth Factor (VEGF) Inhibitor Market, Segmentation By Route Of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    25.4. Canada Vascular Endothelial Growth Factor (VEGF) Inhibitor Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    26. South America Vascular Endothelial Growth Factor (VEGF) Inhibitor Market

    26.1. South America Vascular Endothelial Growth Factor (VEGF) Inhibitor Market Overview

    26.2. South America Vascular Endothelial Growth Factor (VEGF) Inhibitor Market, Segmentation By Drugs Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    26.3. South America Vascular Endothelial Growth Factor (VEGF) Inhibitor Market, Segmentation By Route Of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    26.4. South America Vascular Endothelial Growth Factor (VEGF) Inhibitor Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    27. Brazil Vascular Endothelial Growth Factor (VEGF) Inhibitor Market

    27.1. Brazil Vascular Endothelial Growth Factor (VEGF) Inhibitor Market, Segmentation By Drugs Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    27.2. Brazil Vascular Endothelial Growth Factor (VEGF) Inhibitor Market, Segmentation By Route Of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    27.3. Brazil Vascular Endothelial Growth Factor (VEGF) Inhibitor Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    28. Middle East Vascular Endothelial Growth Factor (VEGF) Inhibitor Market

    28.1. Middle East Vascular Endothelial Growth Factor (VEGF) Inhibitor Market Overview

    28.2. Middle East Vascular Endothelial Growth Factor (VEGF) Inhibitor Market, Segmentation By Drugs Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    28.3. Middle East Vascular Endothelial Growth Factor (VEGF) Inhibitor Market, Segmentation By Route Of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    28.4. Middle East Vascular Endothelial Growth Factor (VEGF) Inhibitor Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    29. Africa Vascular Endothelial Growth Factor (VEGF) Inhibitor Market

    29.1. Africa Vascular Endothelial Growth Factor (VEGF) Inhibitor Market Overview

    29.2. Africa Vascular Endothelial Growth Factor (VEGF) Inhibitor Market, Segmentation By Drugs Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    29.3. Africa Vascular Endothelial Growth Factor (VEGF) Inhibitor Market, Segmentation By Route Of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    29.4. Africa Vascular Endothelial Growth Factor (VEGF) Inhibitor Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    30. Vascular Endothelial Growth Factor (VEGF) Inhibitor Market Competitive Landscape And Company Profiles

    30.1. Vascular Endothelial Growth Factor (VEGF) Inhibitor Market Competitive Landscape

    30.2. Vascular Endothelial Growth Factor (VEGF) Inhibitor Market Company Profiles

    30.2.1. F. Hoffmann-La Roche AG

    30.2.1.1. Overview

    30.2.1.2. Products and Services

    30.2.1.3. Strategy

    30.2.1.4. Financial Performance

    30.2.2. Bayer AG

    30.2.2.1. Overview

    30.2.2.2. Products and Services

    30.2.2.3. Strategy

    30.2.2.4. Financial Performance

    30.2.3. Regeneron Pharmaceuticals Inc.

    30.2.3.1. Overview

    30.2.3.2. Products and Services

    30.2.3.3. Strategy

    30.2.3.4. Financial Performance

    30.2.4. AstraZeneca Plc.

    30.2.4.1. Overview

    30.2.4.2. Products and Services

    30.2.4.3. Strategy

    30.2.4.4. Financial Performance

    30.2.5. Novartis AG

    30.2.5.1. Overview

    30.2.5.2. Products and Services

    30.2.5.3. Strategy

    30.2.5.4. Financial Performance

    31. Vascular Endothelial Growth Factor (VEGF) Inhibitor Market Other Major And Innovative Companies

    31.1. Pfizer Inc.

    31.2. Eli Lilly and Company

    31.3. Exelixis Inc.

    31.4. Amgen Inc.

    31.5. Sanofi S.A.

    31.6. Cipla Limited

    31.7. Biocon

    31.8. Dr. Reddy's Laboratories

    31.9. Chi-Med

    31.10. Innovent Biologics

    31.11. Daiichi Sankyo

    31.12. Chugai Pharmaceutical Co. Ltd

    31.13. AstraZeneca plc

    31.14. Allergan plc.

    31.15. Boehringer Ingelheim International GmbH

    32. Global Vascular Endothelial Growth Factor (VEGF) Inhibitor Market Competitive Benchmarking

    33. Global Vascular Endothelial Growth Factor (VEGF) Inhibitor Market Competitive Dashboard

    34. Key Mergers And Acquisitions In The Vascular Endothelial Growth Factor (VEGF) Inhibitor Market

    35. Vascular Endothelial Growth Factor (VEGF) Inhibitor Market Future Outlook and Potential Analysis

    35.1 Vascular Endothelial Growth Factor (VEGF) Inhibitor Market In 2028 - Countries Offering Most New Opportunities

    35.2 Vascular Endothelial Growth Factor (VEGF) Inhibitor Market In 2028 - Segments Offering Most New Opportunities

    35.3 Vascular Endothelial Growth Factor (VEGF) Inhibitor Market In 2028 - Growth Strategies

    35.3.1 Market Trend Based Strategies

    35.3.2 Competitor Strategies

    36. Appendix

    36.1. Abbreviations

    36.2. Currencies

    36.3. Historic And Forecast Inflation Rates

    36.4. Research Inquiries

    36.5. The Business Research Company

    36.6. Copyright And Disclaimer

List Of Tables

    Table 1: Global Historic Market Growth, 2018-2023, $ Billion
  • Table 2: Global Forecast Market Growth, 2023-2028F, 2033F, $ Billion
  • Table 3: Global Vascular Endothelial Growth Factor (VEGF) Inhibitor Market, Segmentation By Drugs Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 4: Global Vascular Endothelial Growth Factor (VEGF) Inhibitor Market, Segmentation By Route Of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 5: Global Vascular Endothelial Growth Factor (VEGF) Inhibitor Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 6: Global Vascular Endothelial Growth Factor (VEGF) Inhibitor Market, Split By Region, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 7: Global Vascular Endothelial Growth Factor (VEGF) Inhibitor Market, Split By Country, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 8: Asia-Pacific, Vascular Endothelial Growth Factor (VEGF) Inhibitor Market, Segmentation By Drugs Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 9: Asia-Pacific, Vascular Endothelial Growth Factor (VEGF) Inhibitor Market, Segmentation By Route Of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 10: Asia-Pacific, Vascular Endothelial Growth Factor (VEGF) Inhibitor Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 11: China, Vascular Endothelial Growth Factor (VEGF) Inhibitor Market, Segmentation By Drugs Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 12: China, Vascular Endothelial Growth Factor (VEGF) Inhibitor Market, Segmentation By Route Of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 13: China, Vascular Endothelial Growth Factor (VEGF) Inhibitor Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 14: India, Vascular Endothelial Growth Factor (VEGF) Inhibitor Market, Segmentation By Drugs Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 15: India, Vascular Endothelial Growth Factor (VEGF) Inhibitor Market, Segmentation By Route Of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 16: India, Vascular Endothelial Growth Factor (VEGF) Inhibitor Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 17: Japan, Vascular Endothelial Growth Factor (VEGF) Inhibitor Market, Segmentation By Drugs Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 18: Japan, Vascular Endothelial Growth Factor (VEGF) Inhibitor Market, Segmentation By Route Of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 19: Japan, Vascular Endothelial Growth Factor (VEGF) Inhibitor Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 20: Australia, Vascular Endothelial Growth Factor (VEGF) Inhibitor Market, Segmentation By Drugs Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 21: Australia, Vascular Endothelial Growth Factor (VEGF) Inhibitor Market, Segmentation By Route Of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 22: Australia, Vascular Endothelial Growth Factor (VEGF) Inhibitor Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 23: Indonesia, Vascular Endothelial Growth Factor (VEGF) Inhibitor Market, Segmentation By Drugs Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 24: Indonesia, Vascular Endothelial Growth Factor (VEGF) Inhibitor Market, Segmentation By Route Of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 25: Indonesia, Vascular Endothelial Growth Factor (VEGF) Inhibitor Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 26: South Korea, Vascular Endothelial Growth Factor (VEGF) Inhibitor Market, Segmentation By Drugs Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 27: South Korea, Vascular Endothelial Growth Factor (VEGF) Inhibitor Market, Segmentation By Route Of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 28: South Korea, Vascular Endothelial Growth Factor (VEGF) Inhibitor Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 29: Western Europe, Vascular Endothelial Growth Factor (VEGF) Inhibitor Market, Segmentation By Drugs Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 30: Western Europe, Vascular Endothelial Growth Factor (VEGF) Inhibitor Market, Segmentation By Route Of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 31: Western Europe, Vascular Endothelial Growth Factor (VEGF) Inhibitor Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 32: UK, Vascular Endothelial Growth Factor (VEGF) Inhibitor Market, Segmentation By Drugs Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 33: UK, Vascular Endothelial Growth Factor (VEGF) Inhibitor Market, Segmentation By Route Of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 34: UK, Vascular Endothelial Growth Factor (VEGF) Inhibitor Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 35: Germany, Vascular Endothelial Growth Factor (VEGF) Inhibitor Market, Segmentation By Drugs Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 36: Germany, Vascular Endothelial Growth Factor (VEGF) Inhibitor Market, Segmentation By Route Of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 37: Germany, Vascular Endothelial Growth Factor (VEGF) Inhibitor Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 38: France, Vascular Endothelial Growth Factor (VEGF) Inhibitor Market, Segmentation By Drugs Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 39: France, Vascular Endothelial Growth Factor (VEGF) Inhibitor Market, Segmentation By Route Of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 40: France, Vascular Endothelial Growth Factor (VEGF) Inhibitor Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 41: Italy, Vascular Endothelial Growth Factor (VEGF) Inhibitor Market, Segmentation By Drugs Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 42: Italy, Vascular Endothelial Growth Factor (VEGF) Inhibitor Market, Segmentation By Route Of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 43: Italy, Vascular Endothelial Growth Factor (VEGF) Inhibitor Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 44: Spain, Vascular Endothelial Growth Factor (VEGF) Inhibitor Market, Segmentation By Drugs Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 45: Spain, Vascular Endothelial Growth Factor (VEGF) Inhibitor Market, Segmentation By Route Of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 46: Spain, Vascular Endothelial Growth Factor (VEGF) Inhibitor Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 47: Eastern Europe, Vascular Endothelial Growth Factor (VEGF) Inhibitor Market, Segmentation By Drugs Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 48: Eastern Europe, Vascular Endothelial Growth Factor (VEGF) Inhibitor Market, Segmentation By Route Of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 49: Eastern Europe, Vascular Endothelial Growth Factor (VEGF) Inhibitor Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 50: Russia, Vascular Endothelial Growth Factor (VEGF) Inhibitor Market, Segmentation By Drugs Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 51: Russia, Vascular Endothelial Growth Factor (VEGF) Inhibitor Market, Segmentation By Route Of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 52: Russia, Vascular Endothelial Growth Factor (VEGF) Inhibitor Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 53: North America, Vascular Endothelial Growth Factor (VEGF) Inhibitor Market, Segmentation By Drugs Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 54: North America, Vascular Endothelial Growth Factor (VEGF) Inhibitor Market, Segmentation By Route Of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 55: North America, Vascular Endothelial Growth Factor (VEGF) Inhibitor Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 56: USA, Vascular Endothelial Growth Factor (VEGF) Inhibitor Market, Segmentation By Drugs Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 57: USA, Vascular Endothelial Growth Factor (VEGF) Inhibitor Market, Segmentation By Route Of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 58: USA, Vascular Endothelial Growth Factor (VEGF) Inhibitor Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 59: Canada, Vascular Endothelial Growth Factor (VEGF) Inhibitor Market, Segmentation By Drugs Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 60: Canada, Vascular Endothelial Growth Factor (VEGF) Inhibitor Market, Segmentation By Route Of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 61: Canada, Vascular Endothelial Growth Factor (VEGF) Inhibitor Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 62: South America, Vascular Endothelial Growth Factor (VEGF) Inhibitor Market, Segmentation By Drugs Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 63: South America, Vascular Endothelial Growth Factor (VEGF) Inhibitor Market, Segmentation By Route Of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 64: South America, Vascular Endothelial Growth Factor (VEGF) Inhibitor Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 65: Brazil, Vascular Endothelial Growth Factor (VEGF) Inhibitor Market, Segmentation By Drugs Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 66: Brazil, Vascular Endothelial Growth Factor (VEGF) Inhibitor Market, Segmentation By Route Of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 67: Brazil, Vascular Endothelial Growth Factor (VEGF) Inhibitor Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 68: Middle East, Vascular Endothelial Growth Factor (VEGF) Inhibitor Market, Segmentation By Drugs Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 69: Middle East, Vascular Endothelial Growth Factor (VEGF) Inhibitor Market, Segmentation By Route Of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 70: Middle East, Vascular Endothelial Growth Factor (VEGF) Inhibitor Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 71: Africa, Vascular Endothelial Growth Factor (VEGF) Inhibitor Market, Segmentation By Drugs Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 72: Africa, Vascular Endothelial Growth Factor (VEGF) Inhibitor Market, Segmentation By Route Of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 73: Africa, Vascular Endothelial Growth Factor (VEGF) Inhibitor Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 74: F. Hoffmann-La Roche AG Financial Performance
  • Table 75: Bayer AG Financial Performance
  • Table 76: Regeneron Pharmaceuticals Inc. Financial Performance
  • Table 77: AstraZeneca Plc. Financial Performance
  • Table 78: Novartis AG Financial Performance

List Of Figures

    Figure 1: Global Historic Market Growth, 2018-2023, $ Billion
  • Figure 2: Global Forecast Market Growth, 2023-2028F, 2033F, $ Billion
  • Figure 3: Global Vascular Endothelial Growth Factor (VEGF) Inhibitor Market, Segmentation By Drugs Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 4: Global Vascular Endothelial Growth Factor (VEGF) Inhibitor Market, Segmentation By Route Of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 5: Global Vascular Endothelial Growth Factor (VEGF) Inhibitor Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 6: Global Vascular Endothelial Growth Factor (VEGF) Inhibitor Market, Split By Region, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 7: Global Vascular Endothelial Growth Factor (VEGF) Inhibitor Market, Split By Country, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 8: Asia-Pacific, Vascular Endothelial Growth Factor (VEGF) Inhibitor Market, Segmentation By Drugs Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 9: Asia-Pacific, Vascular Endothelial Growth Factor (VEGF) Inhibitor Market, Segmentation By Route Of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 10: Asia-Pacific, Vascular Endothelial Growth Factor (VEGF) Inhibitor Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 11: China, Vascular Endothelial Growth Factor (VEGF) Inhibitor Market, Segmentation By Drugs Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 12: China, Vascular Endothelial Growth Factor (VEGF) Inhibitor Market, Segmentation By Route Of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 13: China, Vascular Endothelial Growth Factor (VEGF) Inhibitor Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 14: India, Vascular Endothelial Growth Factor (VEGF) Inhibitor Market, Segmentation By Drugs Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 15: India, Vascular Endothelial Growth Factor (VEGF) Inhibitor Market, Segmentation By Route Of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 16: India, Vascular Endothelial Growth Factor (VEGF) Inhibitor Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 17: Japan, Vascular Endothelial Growth Factor (VEGF) Inhibitor Market, Segmentation By Drugs Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 18: Japan, Vascular Endothelial Growth Factor (VEGF) Inhibitor Market, Segmentation By Route Of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 19: Japan, Vascular Endothelial Growth Factor (VEGF) Inhibitor Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 20: Australia, Vascular Endothelial Growth Factor (VEGF) Inhibitor Market, Segmentation By Drugs Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 21: Australia, Vascular Endothelial Growth Factor (VEGF) Inhibitor Market, Segmentation By Route Of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 22: Australia, Vascular Endothelial Growth Factor (VEGF) Inhibitor Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 23: Indonesia, Vascular Endothelial Growth Factor (VEGF) Inhibitor Market, Segmentation By Drugs Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 24: Indonesia, Vascular Endothelial Growth Factor (VEGF) Inhibitor Market, Segmentation By Route Of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 25: Indonesia, Vascular Endothelial Growth Factor (VEGF) Inhibitor Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 26: South Korea, Vascular Endothelial Growth Factor (VEGF) Inhibitor Market, Segmentation By Drugs Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 27: South Korea, Vascular Endothelial Growth Factor (VEGF) Inhibitor Market, Segmentation By Route Of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 28: South Korea, Vascular Endothelial Growth Factor (VEGF) Inhibitor Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 29: Western Europe, Vascular Endothelial Growth Factor (VEGF) Inhibitor Market, Segmentation By Drugs Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 30: Western Europe, Vascular Endothelial Growth Factor (VEGF) Inhibitor Market, Segmentation By Route Of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 31: Western Europe, Vascular Endothelial Growth Factor (VEGF) Inhibitor Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 32: UK, Vascular Endothelial Growth Factor (VEGF) Inhibitor Market, Segmentation By Drugs Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 33: UK, Vascular Endothelial Growth Factor (VEGF) Inhibitor Market, Segmentation By Route Of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 34: UK, Vascular Endothelial Growth Factor (VEGF) Inhibitor Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 35: Germany, Vascular Endothelial Growth Factor (VEGF) Inhibitor Market, Segmentation By Drugs Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 36: Germany, Vascular Endothelial Growth Factor (VEGF) Inhibitor Market, Segmentation By Route Of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 37: Germany, Vascular Endothelial Growth Factor (VEGF) Inhibitor Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 38: France, Vascular Endothelial Growth Factor (VEGF) Inhibitor Market, Segmentation By Drugs Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 39: France, Vascular Endothelial Growth Factor (VEGF) Inhibitor Market, Segmentation By Route Of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 40: France, Vascular Endothelial Growth Factor (VEGF) Inhibitor Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 41: Italy, Vascular Endothelial Growth Factor (VEGF) Inhibitor Market, Segmentation By Drugs Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 42: Italy, Vascular Endothelial Growth Factor (VEGF) Inhibitor Market, Segmentation By Route Of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 43: Italy, Vascular Endothelial Growth Factor (VEGF) Inhibitor Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 44: Spain, Vascular Endothelial Growth Factor (VEGF) Inhibitor Market, Segmentation By Drugs Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 45: Spain, Vascular Endothelial Growth Factor (VEGF) Inhibitor Market, Segmentation By Route Of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 46: Spain, Vascular Endothelial Growth Factor (VEGF) Inhibitor Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 47: Eastern Europe, Vascular Endothelial Growth Factor (VEGF) Inhibitor Market, Segmentation By Drugs Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 48: Eastern Europe, Vascular Endothelial Growth Factor (VEGF) Inhibitor Market, Segmentation By Route Of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 49: Eastern Europe, Vascular Endothelial Growth Factor (VEGF) Inhibitor Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 50: Russia, Vascular Endothelial Growth Factor (VEGF) Inhibitor Market, Segmentation By Drugs Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 51: Russia, Vascular Endothelial Growth Factor (VEGF) Inhibitor Market, Segmentation By Route Of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 52: Russia, Vascular Endothelial Growth Factor (VEGF) Inhibitor Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 53: North America, Vascular Endothelial Growth Factor (VEGF) Inhibitor Market, Segmentation By Drugs Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 54: North America, Vascular Endothelial Growth Factor (VEGF) Inhibitor Market, Segmentation By Route Of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 55: North America, Vascular Endothelial Growth Factor (VEGF) Inhibitor Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 56: USA, Vascular Endothelial Growth Factor (VEGF) Inhibitor Market, Segmentation By Drugs Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 57: USA, Vascular Endothelial Growth Factor (VEGF) Inhibitor Market, Segmentation By Route Of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 58: USA, Vascular Endothelial Growth Factor (VEGF) Inhibitor Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 59: Canada, Vascular Endothelial Growth Factor (VEGF) Inhibitor Market, Segmentation By Drugs Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 60: Canada, Vascular Endothelial Growth Factor (VEGF) Inhibitor Market, Segmentation By Route Of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 61: Canada, Vascular Endothelial Growth Factor (VEGF) Inhibitor Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 62: South America, Vascular Endothelial Growth Factor (VEGF) Inhibitor Market, Segmentation By Drugs Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 63: South America, Vascular Endothelial Growth Factor (VEGF) Inhibitor Market, Segmentation By Route Of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 64: South America, Vascular Endothelial Growth Factor (VEGF) Inhibitor Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 65: Brazil, Vascular Endothelial Growth Factor (VEGF) Inhibitor Market, Segmentation By Drugs Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 66: Brazil, Vascular Endothelial Growth Factor (VEGF) Inhibitor Market, Segmentation By Route Of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 67: Brazil, Vascular Endothelial Growth Factor (VEGF) Inhibitor Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 68: Middle East, Vascular Endothelial Growth Factor (VEGF) Inhibitor Market, Segmentation By Drugs Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 69: Middle East, Vascular Endothelial Growth Factor (VEGF) Inhibitor Market, Segmentation By Route Of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 70: Middle East, Vascular Endothelial Growth Factor (VEGF) Inhibitor Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 71: Africa, Vascular Endothelial Growth Factor (VEGF) Inhibitor Market, Segmentation By Drugs Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 72: Africa, Vascular Endothelial Growth Factor (VEGF) Inhibitor Market, Segmentation By Route Of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 73: Africa, Vascular Endothelial Growth Factor (VEGF) Inhibitor Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 74: F. Hoffmann-La Roche AG Financial Performance
  • Figure 75: Bayer AG Financial Performance
  • Figure 76: Regeneron Pharmaceuticals Inc. Financial Performance
  • Figure 77: AstraZeneca Plc. Financial Performance
  • Figure 78: Novartis AG Financial Performance
View Report
View Report
View Report
View Report
View Report
View Report
View Report
View Report

Frequently Asked Questions

What is the definition of the vascular endothelial growth factor (VEGF) inhibitor market?

A VEGF inhibitor is an inhibitor that prevents planned cell death by acting as an anti-apoptotic factor for hematopoietic cells. VEGF increases vascular permeability, which may make it easier for tumours to spread via the bloodstream and receive more oxygen and nutrients. For further insights on the vascular endothelial growth factor (VEGF) inhibitor market, request a sample here

How will the vascular endothelial growth factor (VEGF) inhibitor market drivers and restraints affect the vascular endothelial growth factor (VEGF) inhibitor market dynamics? What forces will shape the vascular endothelial growth factor (VEGF) inhibitor i

The vascular endothelial growth factor (VEGF) inhibitor market growth is aided by growing prevalence of cancer and macular degeneration diseases. However, some vascular endothelial growth factor (VEGF) inhibitor market restraints include side effects caused by VEGF inhibitors. For further insights on the vascular endothelial growth factor (VEGF) inhibitor market, request a sample here

What is the forecast market size or the forecast market value of the vascular endothelial growth factor (VEGF) inhibitor market?

The vascular endothelial growth factor (VEGF) inhibitor market is expected to reach $12.11 billion in 2027 at a rate of 7.8%. For further insights on the vascular endothelial growth factor (VEGF) inhibitor market, request a sample here

How is the vascular endothelial growth factor (VEGF) inhibitor market segmented?

The global vascular endothelial growth factor (VEGF) inhibitor market is segmented as
1) By Drugs Type: Avastin, Tecentriq, Cometriq, Eylea, Other Drug Types
2) By Route Of Administration: Oral, Intravenous
3) By Application: Oncology, Ophthalmology, Other Applications
For further insights on the vascular endothelial growth factor (VEGF) inhibitor market,
request a sample here

Which region has the largest share of the vascular endothelial growth factor (VEGF) inhibitor market? What are the largest region's market size and growth rate?

North America was the largest region in the vascular endothelial growth factor (VEGF) inhibitor market in 2022. For detailed insights on the largest region's market size and growth rate, request a sample here.

Who are the major players in the vascular endothelial growth factor (VEGF) inhibitor market?

Key competitors in the vascular endothelial growth factor (VEGF) inhibitor market are, Pfizer, Amgen, Roche, Xbrane Biopharma AB, Genentech Inc., AstraZeneca plc, Bayer AG, Eli Lilly and Company, Allergan plc. For further insights on the vascular endothelial growth factor (VEGF) inhibitor market, request a sample here.

What are the key trends in the vascular endothelial growth factor (VEGF) inhibitor market?

Major trends influencing the vascular endothelial growth factor (VEGF) inhibitor market include undergoing various collaborations and partnerships to expand their product portfolio by developing new products. For further insights on the vascular endothelial growth factor (VEGF) inhibitor market, request a sample here.

What are the major opportunities in the vascular endothelial growth factor (VEGF) inhibitor market? What are the strategies for the vascular endothelial growth factor (VEGF) inhibitor market?

For detailed insights on the major opportunities and strategies in the vascular endothelial growth factor (VEGF) inhibitor market, request a sample here.

How does the vascular endothelial growth factor (VEGF) inhibitor market relate to the overall economy and other similar markets?

For detailed insights on vascular endothelial growth factor (VEGF) inhibitor market's relation to the overall economy and other similar markets, request a sample here.

What are the latest mergers and acquisitions in the vascular endothelial growth factor (VEGF) inhibitor industry?

For detailed insights on the mergers and acquisitions in the vascular endothelial growth factor (VEGF) inhibitor industry, request a sample here.

What are the key dynamics influencing the vascular endothelial growth factor (VEGF) inhibitor market growth? SWOT analysis of the vascular endothelial growth factor (VEGF) inhibitor market.

For detailed insights on the key dynamics influencing the vascular endothelial growth factor (VEGF) inhibitor market growth and SWOT analysis of the vascular endothelial growth factor (VEGF) inhibitor industry, request a sample here.